- Exchange: NYSE MKT LLC
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Synthetic Biologics Inc
+ Add to WatchlistSYN:US
1.7400 USD 0.0100 0.57%As of 20:04:06 ET on 06/18/2013.
Snapshot for Synthetic Biologics Inc (SYN)
| Open: | 1.7000 | Day's Range: | 1.6700 - 1.7500 | Volume: | 133,227 |
|---|---|---|---|---|---|
| Previous Close: | 1.7500 | 52wk Range: | 1.3400 - 2.5500 | 1-Yr Rtn: | -13.00% |
Key Statistics for SYN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | -0.4400 |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 77.70 |
| Shares Outstanding (M) | 44.65 |
| 30 Day Average Volume | 59,401 |
| Price/Book (mrq) | 6.7634 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SYN
Company Profile & Key Executives for SYN
Synthetic Biologics, Inc. develops synthetic DNA-based therapeutics and disease-modifying medicines. The Company developed, or participated in developing, products to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis.
| Jeffrey Lucero Riley "Jeff"President/CEO | C Evan BallantyneChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
SYN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page